Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021)
Historic Preferred Stock Liabilities for Candel Therapeutics (CADL) over the last 2 years, with Q2 2021 value amounting to $26.6 million.
- Candel Therapeutics' Preferred Stock Liabilities changed N/A to $26.6 million in Q2 2021 from the same period last year, while for Jun 2021 it was $26.6 million, marking a year-over-year change of. This contributed to the annual value of $26.6 million for FY2020, which is N/A changed from last year.
- According to the latest figures from Q2 2021, Candel Therapeutics' Preferred Stock Liabilities is $26.6 million.
- In the past 5 years, Candel Therapeutics' Preferred Stock Liabilities registered a high of $26.6 million during Q4 2020, and its lowest value of $26.6 million during Q4 2020.